The experimental arms of the clinical trials with pembrolizumab + platinum + pemetrexed (KeyNote-189) [1], atezolizumab + carboplatin + paclitaxel + bevacizumab (IMpower-150) [11], and atezolizumab + carboplatin + nab-paclitaxel (IMpower-130) [12] for non-squamous NSCLC, pembrolizumab + platinum + paclitaxel for squamous NSCLC (KeyNote-407) [8], and cemiplimab + platinum doublet (EMPOWER Lung 3) [2] for both squamous and non-squamous NSCLC, all became recommended standard treatments, irrespective of the PD-L1 status. This evidence concerns the gene CD274 and non-small cell lung carcinoma.